AUPH News and Press, Aurinia Pharmaceuticals Inc From 03/05/24

2024-03-05 15:27:16 ET Summary AUPH's strategic review did not result in an acquisition of the company, nor the company acquiring an asset. AUPH has decided to buy back its own stock and focus on Lupkynis. The buyback could provide support for the stock near-term, although a r...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in an...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen’s 44th Annual Health Care Conference taking place March 4 - 6, 2024, at the Ma...

2024-02-18 11:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 66.7% to $3.76 on volume of 298,289,429 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 70.5% to $0.1091 on volume of 172,174,410 shares Sientra Inc. (SIEN) rose 89.9% to $0.342 on volume of ...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 62.5% to $3.665 on volume of 269,509,234 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 64.1% to $0.105 on volume of 159,463,786 shares Sientra Inc. (SIEN) rose 119.4% to $0.395 on volume of...

2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...

2024-02-15 10:10:28 ET Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Conference Call February 15, 2024 08:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer J...

2024-02-15 07:05:36 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharma GAAP EPS of -$0.19 misses by $0.03, revenue of $45.1M misses by $0.06M Aurini...

2024-02-15 06:02:11 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.19 misses by $0.03 . Revenue of $45.1M (+58.8% Y/Y) misses by $0.06M . Shares -3.6% PM. $350.7 million of cash, cash equivalents, restricted cash and investment...